Context Nonpharmacological treatments with little
patient cost or risk are useful supplements to pharmacotherapy in the
treatment of patients with chronic illness. Research has demonstrated
that writing about emotionally traumatic experiences has a surprisingly
beneficial effect on symptom reports, well-being, and health care use
in healthy individuals.
Objective To determine if writing about stressful life experiences
affects disease status in patients with asthma or rheumatoid
arthritis using standardized quantitative outcome measures.
Design Randomized controlled trial conducted between October 1996
and December 1997.
Setting Outpatient community residents drawn from
private and institutional practice.
Patients Volunteer sample of 112 patients with asthma
(n=61) or rheumatoid arthritis (n=51)
received the intervention; 107 completed the study, 58 in the asthma
group and 49 in the rheumatoid arthritis group.
Intervention Patients were assigned to write either about the most
stressful event of their lives (n=71; 39 asthma, 32
rheumatoid arthritis) or about emotionally neutral topics
(n=41; 22 asthma, 19 rheumatoid arthritis) (the control
intervention).
Main Outcome Measures Asthma patients were evaluated with
spirometry and rheumatoid arthritis patients were clinically examined
by a rheumatologist. Assessments were conducted at baseline and at 2
weeks and 2 months and 4 months after writing and were done blind to
experimental condition.
Results Of evaluable patients 4 months after treatment, asthma
patients in the experimental group showed improvements in lung function
(the mean percentage of predicted forced expiratory volume in 1 second
[FEV1] improved from 63.9% at baseline to 76.3% at the
4-month follow-up; P<.001), whereas control group patients
showed no change. Rheumatoid arthritis patients in the experimental
group showed improvements in overall disease activity (a mean reduction
in disease severity from 1.65 to 1.19 [28%] on a scale of 0
[asymptomatic] to 4 [very severe] at the 4-month follow-up;
P=.001), whereas control group patients did
not change. Combining all completing patients, 33 (47.1%) of 70
experimental patients had clinically relevant improvement, whereas 9
(24.3%) of 37 control patients had improvement
(P=.001).
Conclusion Patients with mild to moderately severe asthma or
rheumatoid arthritis who wrote about stressful life experiences had
clinically relevant changes in health status at 4 months compared with
those in the control group. These gains were beyond those attributable
to the standard medical care that all participants were receiving. It
remains unknown whether these health improvements will persist beyond 4
months or whether this exercise will prove effective with other
diseases.
A growing
amount of literature suggests that addressing patients' psychological
needs produces both psychological and physical health
benefits.1-3 Expressive writing is one such technique that
has been used successfully in several controlled
studies.4-6 A brief written emotional expression exercise
developed by Pennebaker and Beall7 has been tested in
studies of health benefits in healthy persons. It calls for
participating subjects to write an essay, typically during a 3-day
period, expressing their thoughts and feelings about a traumatic
experience. Differences have been found between control subjects (who
write about innocuous topics) and experimental subjects in frequency of
subsequent health center visits, subjective well-being, and immune
function.8-10 A recent meta-analysis of this written
emotional expression exercise concluded that the procedure reliably
improved health outcomes.11
Prior studies have not addressed the clinical relevance of these
findings, in part because their samples were physically healthy people.
It is not clear that the effects extend to individuals with medical
conditions. Prior studies were
also limited to indirect measures of disease
(eg, liver enzyme function, health center visits) or to self-reported
assessments.11 While important outcomes in their own right,
self-reported symptoms are susceptible to many biases.12
Therefore, we used outcomes more closely related to disease status.
This study examined whether writing about stressful experiences affects
objective measures of disease status in patients with chronic asthma or
rheumatoid arthritis (RA). We chose these 2 diseases because they are
common, cause substantial personal and economic burden, and are chronic
conditions affecting daily life. As writing produces health benefits in
healthy people, we hypothesized that patients assigned to the
experimental group would show improvements in outcomes 4 months after
writing compared with a control group. We also hypothesized that health
changes would be of clinically significant magnitudes.
Participants were volunteers recruited from local communities who
had asthma or RA. Diagnoses were confirmed in the RA group by a
board-certified rheumatologist and all participants met American
College of Rheumatology criteria. Asthma was diagnosed by a history of
asthma confirmed by a physician; patients were also required to provide
a documented reduction in expiratory function (either in physician
records or when evaluated by study staff). Advertisements were posted
in local newspapers and at nearby hospitals and medical practices,
seeking individuals with asthma or RA to "participate in a study of
your daily experience of illness." Interested participants were
screened by telephone to determine eligibility and to collect
demographic and other data used to characterize participants vs
nonparticipants. Exclusion criteria included the following: (1) ongoing
psychotherapy or having a defined psychiatric disorder, (2) using a
medication that could interfere with symptom report (eg, mood-altering
medications) or taking more than 10 mg of prednisone daily, (3) being
deemed unable to comply with the protocol (either self-selected or by
indicating during screening that he or she could not attend sessions or
complete all requested tasks), and (4) being unable to write for a
duration of 20 minutes. Participants received $50 for completing the
entire protocol, which was conducted between October 1996 and December
1997.
Approval was obtained from both the State University of New York at
Stony Brook and the University Hospital human subjects review boards.
Informed consent was obtained from interested and eligible patients for
randomization and for medical examinations at the first visit to our
laboratory. Consenting patients completed baseline questionnaires,
which included demographic information, measures of disease severity
and quality of life,13,14 and a variety of psychological
questionnaires to be used in future examinations of individual
differences in response to this intervention.15-23
Participants were asked to write for 20 minutes on 3 consecutive
days a week after completing baseline assessments. Writing took place
in private rooms located in our laboratory to ensure confidentiality.
All participants were given a writing tablet containing an insert with
writing instructions. Participants in the experimental group (39
asthma, 32 RA) were assigned to write about the most stressful
experience that they had ever undergone, while the participants in the
control group were asked to describe their plans for the day.
Expectancy differences were minimized by informing both groups that we
were interested in their experience of stress. Experimental
participants were explicitly writing about stressful life experiences,
while control group writing was framed as a time-management exercise to
reduce stress. Participants were asked to write continuously, without
regard for spelling or stylistic concerns, and were signaled to stop
after 20 minutes. Participants could write about a topic for 3
sessions, or move from one topic to another (they were asked to repeat
a previous topic, if necessary, rather than stop early). All essays
were anonymous and were returned by dropping the writing tablet into a
sealed box. Participants did not discuss their writing with project
staff, and participants were never in contact with one another as part
of the study (eg, in a waiting room).
Sample-Size Determination
A recent meta-analysis11 suggests that the effect
size of this exercise in healthy samples is
d=0.47, although effect sizes for the measures
used in this study are likely to be closer to
d=0.68. Power computations for an unbalanced
design indicate that an overall total of 120 should be sufficient to
achieve 80% power with 2-tailed tests and α=.05.
Disease activity outcomes were evaluated at baseline, 2 weeks, 2
months, and 4 months after writing. (Self-assessments of the
psychosocial environment were also collected by participants for 1 week
prior to and 2 weeks following the writing exercise, but these results
are not presented herein.) The pulmonary function of patients with
asthma was assessed in the laboratory by spirometry (Renaissance,
Nellcor Puritan Bennett, Mallinckrodt, St Louis, Mo), following the
guidelines put forth by the American Thoracic Society. The primary
outcome measure was forced expiratory volume in 1 second
(FEV1). Evaluations of RA patients were made with a
structured interview completed by the treating rheumatologist. It is a
modification of that used by Affleck and colleagues,24 and
reflects the recent shift away from entirely qualitative to more
quantitative, standardized methods.25 The interview
requires the physician to rate diagnostic symptoms, a global assessment
of disease activity, symptom severity, distribution of pain,
tenderness, and swelling throughout the affected joints, presence and
severity of deformities,
assessment of daily living capacity, and general
psychosocial functioning. The primary outcome measure for this study
was the physician's global assessment of patients' current clinical
status, which has been recommended for use in RA clinical
trials.26,27 Each RA patient had 4 clinical examinations
completed by the same physician. Several physicians conducted
evaluations for the study. These measures not only represent the core
symptoms of the 2 diseases but also represent contrasting approaches
to illness evaluation (1 biomechanical, 1 clinical interview). All
raters were unaware of experimental condition.
In addition to overall intervention group comparisons from baseline to
final follow-up, analyses examining the clinical relevance of observed
changes and the time-course of changes were planned in advance. Group
differences were evaluated with analysis of covariance, testing the
effect of group (control vs experimental) at 4 months following
writing, statistically controlling for baseline levels. Clinical
relevance was tested by examining the distribution of patients who met
our criteria for clinically relevant improvement in each group, using
χ2 analyses. Finally, the time course of changes was
examined using repeated measures analysis of covariance including terms
representing the effect of group, time, and the interaction of group
and time.
Random Assignment and Masking
An unbalanced design with greater numbers of participants
assigned to the experimental than the control condition (35:21 for RA,
48:22 for asthma, respectively) was used to enhance later exploration
of the experimental group (14 patients dropped out of the study before
receiving the intervention). After entering the study and completing
baseline assessments, participants were randomized into the control or
experimental group using a computer-generated random assignment scheme,
which assigned 2 of every 3 patients (within disease group) to the
experimental condition. This strategy also provided comparable seasonal
effects for control and experimental groups. Assignments were kept in
sealed opaque envelopes until participants were scheduled to complete
the writing intervention, at which point the research coordinator
prepared intervention instructions specific to group assignment. These
instructions were then handed to patients who were instructed to open
them in privacy. Neither patients nor physicians were informed of the
assignment. There was no indication that either patients or physicians
attempted to compromise blinding procedures. Statistical analyses were
conducted primarily by the first author, who was aware of group
assignment.
We received 465 telephone calls expressing interest in the study,
222 from asthma patients and 243 from RA patients. Among the asthma
patients, 31 callers (14.0%) were interested but not eligible, 73
(32.9%) were eligible but said they were not interested in
participating because of the time commitment, 32 (14.4%) were not
interested and did not provide eligibility information, and project
staff were not able to contact the remaining 16 (7.2%). Among the RA
patients, 35 callers (14.4%) were interested but not eligible, 49
(20.2%) were eligible but not interested because of the time
commitment, 87 (35.8%) were not interested and did not provide
eligibility information, and project staff were not able to contact the
remaining 16 (6.6%). This resulted in 126 eligible and
interested callers who initiated participation
in the study. These subjects did not differ on any demographic measures
(age, sex, number of children, education, employment status, income;
all P values >.10) from individuals ineligible or not
interested. After beginning the study, 14 participants (11%) dropped
out before completing the written disclosure exercise—9 from the
asthma group and 5 from the RA group. All participants exiting the
study were debriefed. Four participants cited current life events
(divorce, the development of a neurological disorder, death of a close
friend, and being recently unemployed and constantly interviewing for
new jobs). One participant was unable to participate due to work
constraints. The remaining 9 participants indicated that they were too
busy with personal issues. This information is summarized in a trial
profile (Figure 1).
Baseline sample characteristics for each disease group are shown in
Table 1. The sample represents the
typical distribution of these diseases and is representative of the
geographic area from which it was drawn.
Control and experimental groups did not differ (using an α of
P<.20) at baseline on demographic measures (age, sex, number
of children, education, employment status, income), health behaviors
(regular medication use, exercise, smoking), or psychological measures
(alexithymia, intrusive and avoidant thoughts, coping strategies, or
anxiety). Baseline disease severity did not differ between control and
experimental groups for asthma outcomes (FEV1, FEV1/forced vital capacity [FVC], quality of life) or RA
outcomes (overall disease activity, RA symptoms, joint pain, joint
swelling).
The first hypothesis was that the experimental group, relative to the
control group and controlling for baseline levels of disease, would
show improvements in objective health indicators 4 months after
writing. In patients with asthmas, writing about emotionally traumatic
events was related to significantly greater improvement in
FEV1, compared with controls
(F1,55=15.11, P<.001;
Figure 2). The same effect was found
for overall rheumatic disease activity, for which writing was related
to significant reductions in disease activity
(F1,46=11.48,
P=.001; Figure 2). These results confirm the
hypothesis that writing about emotionally traumatic experiences reduced
symptoms in individuals with chronic illness. These primary analyses
were replicated using nonparametric statistics, which require many
fewer assumptions about the distribution of the data, to ensure that
the findings were robust. For both RA and asthma groups, no control vs
experimental difference was observed at baseline (Wilcoxon
matched-pairs signed-rank test z=0.07,
P>.20; z=−0.61,
P>.20, respectively), but a strong difference was found at
the 4-month follow-up (Wilcoxon matched-pairs signed-rank test
z=3.41, P<.001;
z=−2.42,
P=.016).
The second hypothesis concerned the clinical significance of
observed differences. To quantify patient change over 4 months, we
defined 3 categories of change, which include the following:
improvement, no significant change, and worsening (defined by baseline
to 4-month follow-up change). For patients with asthma, improvements of
15% or greater in FEV1 over pretreatment values were
defined as improvement, whereas worsening was 15% or greater decline
from pretreatment values. The overall rating of disease activity used
for RA patients was categorical (asymptomatic, mild, moderate, severe,
very severe), so we followed published guidelines that a shift in 1
category to another is a clinically significant change.28 A
shift of 1 or more categories toward asymptomatic defined improvement,
and a worsening condition was by moving 1 or more categories toward
very severe. (No participants shifted more than 2 categories in either
direction over the course of the study.)
Experimental group participants showed greater rates of
improvement and lesser rates of worsening than the control group across
both diseases
(χ22=10.42,
P=.005; Fisher exact P<.006;
Table 2). Across all groups, 33
experimental patients (47.1%) improved according to these criteria,
whereas 9 of control patients (24.3%) improved. Adopting a more
conservative intent-to-treat approach, we replicated these results by
including all patients who had not completed the study in the "no
change" group (χ22=10.38,
P=.006; Fisher exact P<.007; Table
2). These results support our second hypothesis, that observed changes
in health status are clinically significant.
We were also interested in understanding how outcomes changed
over time, and added the 2-week and 2-month data to the analysis. For
asthma patients, the effect of group remained significant
(F1,55=31.37,
P=.003), indicating improvement in the
experimental group across all 3 follow-up evaluations. The effects of
time (F2,110=1.54, P>.20) and
group × time (F2,110=2.20,
P=.13) were not significant, indicating that
the observed improvement was consistent over time (Table
3). For RA patients, 1 of whom did not have
data at time 2, the main effects of group
(F1,45=0.13, P>.70) and time
(F2,90=2.17,
P=.12) were not significant. The effect of
group × time (F2,90=6.13,
P<.01) was significant. We examined this interaction by
testing the effect of group at each point for RA patients. It was not
significant at time 2 or 3 (P values >.30), but was
significant at time 4 (F1,45=9.32,
P=.004), indicating the RA experimental and
control groups did not differ until the 4-month follow-up (Table 3). Means (and SEs) for each time point, by group assignment, are shown in
Table 3.
This is the first study to demonstrate that writing about
stressful life experiences improves physician ratings of disease
severity and objective indices of disease severity in chronically ill
patients. These findings extend our knowledge about this writing
exercise from self-reported symptom and health use outcomes observed in
healthy individuals. Not only were these effects reliably observed 4
months following the structured writing, they appear clinically
meaningful. Approximately 47% of experimental patients vs 24% of
control patients met criteria for clinically relevant improvement.
Thus, both of the study's primary hypotheses were confirmed. Although
it may be difficult to believe that a brief writing exercise can
meaningfully affect health, this study replicates in a chronically ill
sample what a burgeoning literature indicates in healthy individuals.
Mechanisms underlying these effects have not been established, although
several have been proposed.
Observation of participants in similar writing conditions show
that they report considerable emotional upset during the writing
sessions; concomitant alterations in psychophysiological measures (eg,
heart rate, blood pressure) are also observed.29
Additionally, several studies have shown alterations in functional
immune measures following the writing exercise.10,30,31 It
is possible that such affective or physiological responses can explain
our results. Alternatively, participants' cognitive and memory
representation of past traumas may be altered by this writing exercise,
perhaps facilitating improvements in coping with stressful
events.11,32 The most common topics patients wrote about
were the death of a loved one, serious problems of a close other,
problems in relationships, and, on rare occasions, seeing or being in a
major disaster such as a train or car wreck. Alterations of health
behaviors (eg, medication compliance, smoking, and alcohol consumption)
in response to the exercise could also improve health, although there
is currently little support for this explanation.11 These
speculations require examination in the context of studies in which
physiological and behavioral factors are explicitly tested as mediators
of illness outcomes.
The time course of change in the primary outcomes (a secondary
analysis) showed that asthmatic patients in the experimental group
improved within 2 weeks, whereas change for the RA patients was not
evident until the 4-month assessment. We did not predict this pattern
of response and therefore view it cautiously. Nevertheless, the finding
implies that mechanisms underlying improvements, possibly immune
response, may differ in the 2 diseases.
Despite the study's experimental design and the robust results,
we have several concerns about translating these results into
supplemental treatments for chronic diseases. First, although our
4-month follow-up data demonstrate the importance of the effects, it is
unclear if effects will persist beyond this period. Second, patients
with only 2 diseases, asthma and RA, were examined in this study, and
the results may not generalize to other acute or chronic conditions.
Third, it is clear from the clinical improvement analyses that
approximately half of the patients in both control and experimental
groups did not respond to the exercise, and additional research should
explore the characteristics of responders. Fourth, until the mechanism
underlying the findings is identified, we cannot
say how the exercise will interact with other treatments for the
diseases.
Since Engel's classic article introducing the biopsychosocial
model,33 the medical community has come to recognize the
importance of psychological and social factors in preventing and
treating illness. This research shows that a psychological
exercise—writing about emotionally stressful experiences—can reduce
symptoms of 2 chronic diseases. These provocative yet preliminary
results lead us to endorse further research on structured writing and
illness.
1.Fawzy I, Fawzy N, Hyun C.
et al. Malignant
melanoma: effects of an early structured psychiatric intervention,
coping, and affective state on recurrence and survival 6 years later.
Arch Gen Psychiatry.1993;50:681-689.Google Scholar 2.Mumford E, Schlesinger HJ, Glass GV. Reducing medical
costs through mental health treatment: research problems and
recommendations. Broskowski A, Marks E, Budman SH, eds. In:
Linking Health and Mental Health. Beverly Hills, Calif: Sage;
1983:257-273.
3.Spiegel D, Bloom J, Kraemer H, Gottheil E. Effects of
psychosocial treatment on survival of patients with metastatic breast
cancer.
Lancet.1989;2:888-891.Google Scholar 4.Donnelly DA, Murray EJ. Cognitive and emotional changes
in written essays and therapy interviews.
J Soc Clin Psychol.1991;10:334-350.Google Scholar 5.L'Abate L, Boyce J, Russ D, Bird G. Programmed writing:
two follow-ups and one application with clinical out-patients.
Contem Psychodynamics.In press.Google Scholar 6.Murray E, Segal D. Emotional processing in vocal and
written expression of feelings about traumatic experiences.
J
Trauma Stress.1994;7:391-405.Google Scholar 7.Pennebaker JW, Beall SK. Confronting a traumatic event:
toward an understanding of inhibition and disease.
J Abnorm
Psychol.1986;95:274-281.Google Scholar 8.Greenberg MA, Stone AA. Emotional disclosure about
traumas and its relation to health: effects of previous disclosure and
trauma severity.
J Pers Soc Psychol.1992;63:75-84.Google Scholar 9.Pennebaker JW, Colder M, Sharp LK. Accelerating the
coping process.
J Pers Soc Psychol.1990;58:528-537.Google Scholar 10.Pennebaker JW, Kiecolt-Glaser J, Glaser R. Disclosure
of traumas and immune function: health implications for psychotherapy.
J Consult Clin Psychol.1988;56:239-245.Google Scholar 11.Smyth JM. Written emotional expression: effect sizes,
outcome types, and moderating variables.
J Consult Clin
Psychol.1998;66:174-184.Google Scholar 12.Cohen S, Williamson GM. Stress and infectious disease
in humans.
Psychol Bull.1991;109:5-24.Google Scholar 13.Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2: the content and properties of a revised and expanded
arthritis impact measurement scales health status questionnaire.
Arthritis Rheum.1992;35:1-10.Google Scholar 14.Juniper E, Guyatt G, Ferrie P, Griffith L. Measuring
quality of life in asthma.
Am Rev Respir Dis.1993;147:832-838.Google Scholar 15.Spielberger CD, Gorsuch RL, Lushene RE. Manual for
the State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting
Psychologists Press; 1970.
16.Beck AT. Depression: Causes and Treatments. Philadelphia: University of Pennsylvania Press; 1967.
17.Procidano ME, Heller K. Measures of perceived social
support from friends and from family: three validation studies.
Am
J Community Psychol.1983;11:1-24.Google Scholar 18.Carver C, Schier M, Weintraub J. Assessing coping
strategies: a theoretically based approach.
J Pers Soc
Psychol.1989;56:267-283.Google Scholar 19.Cohen S, Kamarck T, Mermelstein R. A global measure of
perceived stress.
J Health Soc Behav.1983;24:385-396.Google Scholar 20.Bagby M, Parker J, Taylor G. The twenty-item Toronto
alexithymia scale-I: item selection and cross-validation of the factor
structure.
J Psychosom Res.1994;38:23-32.Google Scholar 21.Marlowe D, Crowne DP. Social desirability and response
to perceived situational demands.
J Consult Psychol.1961;25:109-115.Google Scholar 22.Greenberg MA, Stone AA, Wortman CB. Health and
psychological effects of emotional disclosure: a test of the
inhibition-confrontation approach.
J Pers Soc Psychol.1996;71:588-602.Google Scholar 23.Horowitz M, Wilner N, Alvarez W. Impact of event scale:
a measure of subjective stress.
Psychosom Med.1979;41:209-218.Google Scholar 24.Affleck G, Tennen H, Urrows S, Higgins P. Neuroticism
and the pain-mood relation in rheumatoid arthritis: insights from a
prospective daily study.
J Consult Clin Psychol.1992;60:119-126.Google Scholar 25.Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ. Self-report questionnaire scores in rheumatoid arthritis
compared with traditional physical, radiographic, and laboratory
measures.
Ann Intern Med.1989;110:259-266.Google Scholar 26.Tugwell P, Boers M.for the OMERACT Committee. Proceedings of the OMERACT conferences on outcome measures in
rheumatoid arthritis clinical trials, Maastrict, the Netherlands.
J Rheumatol.1993;20:527-591.Google Scholar 27.Felson DT, Anderson JJ, Boers M.
et al. The American
College of Rheumatology preliminary core set of disease activity
measures for rheumatoid arthritis clinical trials.
Arthritis
Rheum.1993;36:729-740.Google Scholar 28.Paulus HE, Bulpitt KJ. Rheumatoid arthritis: outcome
measures.
Rheum Dis Clin North Am.1995;21:605-618.Google Scholar 29.Pennebaker JW, Hughes CF, O'Heeron, RC. The
psychophysiology of confession: linking inhibitory and psychosomatic
processes.
J Pers Soc Psychol.1987;52:781-793.Google Scholar 30.Esterling BA, Antoni MH, Fletcher MA, Margulies S, Schneiderman N. Emotional disclosure through writing or speaking
modulates latent Epstein-Barr virus antibody titers.
J Consult
Clin Psychol.1994;62:130-140.Google Scholar 31.Petrie KJ, Booth R, Pennebaker JW, Davison KP, Thomas M. Disclosure of trauma and immune response to hepatitis B vaccination
program.
J Consult Clin Psychol.1995;63:787-792.Google Scholar 32.Smyth JM, Pennebaker JW. Sharing one's story:
translating emotional experiences into words as a coping tool. In:
Snyder CR, ed. Coping: The Psychology of What Works. New York,
NY: Oxford University Press Inc. In press.
33.Engel GL. The need for a new medical model: a
challenge for biomedicine.
Science.1977;196:129-136.Google Scholar